Pui Shan Chow

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4837431/publications.pdf

Version: 2024-02-01

81900 133252 4,280 121 39 59 citations g-index h-index papers 121 121 121 3453 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Boundary lubrication performance of polymeric and organic friction modifiers in the presence of an anti-wear additive. Tribology International, 2022, 165, 107256.	5.9	16
2	Tactile friction and rheological studies to objectify sensory properties of topical formulations. Journal of Rheology, 2022, 66, 305-326.	2.6	7
3	Developing Eco-Friendly Skin Care Formulations with Microemulsions of Essential Oil. Cosmetics, 2022, 9, 30.	3.3	9
4	Influence of wall slip, thixotropy and lubrication regime on the instrumental sensory evaluation of topical formulations. International Journal of Cosmetic Science, 2022, 44, 271-288.	2.6	3
5	Relating Alkyl Chain Length of Additives to Wax Crystallization Inhibition: Toward the Rational Design of Pour Point Depressants. Crystal Growth and Design, 2022, 22, 4031-4042.	3.0	2
6	Influence of structural factors on the tribological performance of organic friction modifiers. Friction, 2021, 9, 380-400.	6.4	25
7	Understanding the Salt-Dependent Outcome of Glycine Polymorphic Nucleation. Pharmaceutics, 2021, 13, 262.	4.5	12
8	Effect of temperature on tribological performance of organic friction modifier and anti-wear additive: Insights from friction, surface (ToF-SIMS and EDX) and wear analysis. Tribology International, 2021, 157, 106896.	5.9	22
9	Influence of Base oil Polarity on the Tribological Performance of Surface-Active Engine Oil Additives. Tribology Letters, 2021, 69, 1.	2.6	7
10	Behavior and interaction of boundary lubricating additives on steel and DLC-coated steel surfaces. Tribology International, 2021, 164, 107199.	5.9	17
11	Mechanistic insights into the effect of structural factors on film formation and tribological performance of organic friction modifiers. Tribology International, 2021, 164, 107243.	5.9	10
12	Molecular dynamics simulations to elucidate translocation and permeation of active from lipid nanoparticle to skin: complemented by experiments. Nanoscale, 2021, 13, 12916-12928.	5.6	19
13	The Crystallization of Active Pharmaceutical Ingredients with Low Melting Points in the Presence of Liquid–Liquid Phase Separation. Crystals, 2021, 11, 1326.	2.2	3
14	Preparation of quercetin nanorod/microcrystalline cellulose formulation via fluid bed coating crystallization for dissolution enhancement. International Journal of Pharmaceutics, 2020, 576, 118983.	5.2	16
15	Encapsulation of Ferulic Acid in Lipid Nanoparticles as Antioxidant for Skin: Mechanistic Understanding through Experiment and Molecular Simulation. ACS Applied Nano Materials, 2020, 3, 5351-5361.	5.0	24
16	Microemulsion composed of combination of skin beneficial oils as vehicle: Development of resveratrol-loaded microemulsion based formulations for skin care applications. Colloids and Surfaces B: Biointerfaces, 2020, 194, 111161.	5.0	30
17	Viscosity Prediction of Lubricants by a General Feed-Forward Neural Network. Journal of Chemical Information and Modeling, 2020, 60, 1224-1234.	5.4	15
18	Development of microemulsion based topical ivermectin formulations: Pre-formulation and formulation studies. Colloids and Surfaces B: Biointerfaces, 2020, 189, 110823.	5.0	44

#	Article	IF	CITATIONS
19	Atomistic Simulation To Understand Anisotropic Growth Behavior of Naproxen Crystal in the Presence of Polymeric Additives. Crystal Growth and Design, 2019, 19, 3768-3776.	3.0	21
20	Continuous and Scalable Process for the Production of Hollow Crystals of a Poorly Water-Soluble Active Pharmaceutical Ingredient for Dissolution Enhancement and Inhaled Delivery. Crystal Growth and Design, 2019, 19, 3402-3409.	3.0	3
21	Agomelatine–hydroquinone (1:1) cocrystal: novel polymorphs and their thermodynamic relationship. Acta Crystallographica Section B: Structural Science, Crystal Engineering and Materials, 2019, 75, 969-977.	1.1	3
22	Antibiotic elution and mechanical property of TiO2 nanotubes functionalized PMMA-based bone cements. Journal of the Mechanical Behavior of Biomedical Materials, 2019, 91, 91-98.	3.1	27
23	Elucidating the Complex Phase Behavior of a Cocrystal System Containing Two APIs and One Coformer. Crystal Growth and Design, 2019, 19, 157-165.	3.0	5
24	Cocrystals of zonisamide: physicochemical characterization and sustained release solid forms. CrystEngComm, 2018, 20, 2923-2931.	2.6	24
25	Polymer Templated Structural Evolution of a Poorly Water-Soluble Active Pharmaceutical Ingredient from Nanoparticles to Hierarchical Crystals. Crystal Growth and Design, 2018, 18, 3089-3098.	3.0	6
26	Reply to the  Comment on "Trimorphs of a pharmaceutical cocrystal involving two active pharmaceutical ingredients: potential relevance to combination drugsâ€-by S. Aitipamula, P. S. Chow and R. B. H. Tan, <i>CrystEngComm</i> , 2009, 11 , 1823'. CrystEngComm, 2018, 20, 373-374.	2.6	0
27	Effect of API-Polymer Miscibility and Interaction on the Stabilization of Amorphous Solid Dispersion: A Molecular Simulation Study. Industrial & Engineering Chemistry Research, 2017, 56, 12698-12707.	3.7	45
28	Anisotropic Crystal Growth Inhibition by Polymeric Additives: Impact on Modulation of Naproxen Crystal Shape and Size. Crystal Growth and Design, 2017, 17, 4844-4854.	3.0	37
29	Stability of Pharmaceutical Cocrystal During Milling: A Case Study of 1:1 Caffeine–Glutaric Acid. Crystal Growth and Design, 2017, 17, 4064-4071.	3.0	28
30	Novel solid forms of oxaprozin: cocrystals and an extended release drug–drug salt of salbutamol. RSC Advances, 2016, 6, 34110-34119.	3.6	28
31	Particle Size Control in Batch Crystallization of Pyrazinamide on Different Scales. Organic Process Research and Development, 2016, 20, 2100-2107.	2.7	12
32	Effects of Common Inorganic Salts on Glycine Polymorphic Transformation: An Insight into Salt-Dependent Polymorphic Selectivity. Crystal Growth and Design, 2016, 16, 6499-6505.	3.0	17
33	Online Classification of Mixed Co-Crystal and Solute Suspensions using Raman Spectroscopy. Organic Process Research and Development, 2016, 20, 1068-1074.	2.7	12
34	Thermal and in Situ X-ray Diffraction Analysis of a Dimorphic Co-Crystal, 1:1 Caffeine–Glutaric Acid. Crystal Growth and Design, 2016, 16, 578-586.	3.0	24
35	Salt-dependent growth kinetics in glycine polymorphic crystallization. CrystEngComm, 2016, 18, 462-470.	2.6	15
36	Crystallizing Micronized Particles of a Poorly Water-Soluble Active Pharmaceutical Ingredient: Nucleation Enhancement by Polymeric Additives. Crystal Growth and Design, 2016, 16, 749-758.	3.0	32

#	Article	IF	CITATIONS
37	Pore size effect on the stabilization of amorphous drug in a mesoporous material: Insights from molecular simulation. Microporous and Mesoporous Materials, 2016, 221, 117-122.	4.4	18
38	Robust Crystallization Process Development for the Metastable \hat{l} -form of Pyrazinamide. Organic Process Research and Development, 2015, 19, 1987-1996.	2.7	18
39	Novel pharmaceutical cocrystals of triflusal: crystal engineering and physicochemical characterization. CrystEngComm, 2015, 17, 9323-9335.	2.6	14
40	Growth Behaviors of Two Similar Crystals: The Great Difference. Crystal Growth and Design, 2015, 15, 1082-1088.	3.0	27
41	Antisolvent Crystallization and Polymorph Screening of Glycine in Microfluidic Channels Using Hydrodynamic Focusing. Crystal Growth and Design, 2015, 15, 3299-3306.	3.0	35
42	Preparation of \hat{l}^2 -carotene nanoparticles by antisolvent precipitation under power ultrasound. Journal of Nanoparticle Research, 2014, 16, 1.	1.9	2
43	Polymorphism in cocrystals: a review and assessment of its significance. CrystEngComm, 2014, 16, 3451.	2.6	242
44	Cocrystallization with flufenamic acid: comparison of physicochemical properties of two pharmaceutical cocrystals. CrystEngComm, 2014, 16, 5793.	2.6	60
45	Crystal Engineering of Tegafur Cocrystals: Structural Analysis and Physicochemical Properties. Crystal Growth and Design, 2014, 14, 6557-6569.	3.0	35
46	Probing the Mechanisms Underlying Electrolyte-Assisted Nucleation Enhancement of <scp>dl</scp> -Alanine. Crystal Growth and Design, 2014, 14, 1406-1411.	3.0	6
47	Design Space for Polymorphic Co-crystallization: Incorporating Process Model Uncertainty and Operational Variability. Crystal Growth and Design, 2014, 14, 3949-3957.	3.0	14
48	Pharmaceutical Salts of Haloperidol with Some Carboxylic Acids and Artificial Sweeteners: Hydrate Formation, Polymorphism, and Physicochemical Properties. Crystal Growth and Design, 2014, 14, 2542-2556.	3.0	43
49	Novel solid forms of the anti-tuberculosis drug, Isoniazid: ternary and polymorphic cocrystals. CrystEngComm, 2013, 15, 5877.	2.6	97
50	Resolving the longstanding riddle of pH-dependent outcome of glycine polymorphic nucleation. CrystEngComm, 2013, 15, 1218.	2.6	40
51	The solvates and salt of antibiotic agent, nitrofurantoin: structural, thermochemical and desolvation studies. CrystEngComm, 2013, 15, 878-889.	2.6	38
52	Improved C-control of crystallization with reduced calibration effort via conductometry. Chemical Engineering Science, 2013, 97, 126-138.	3.8	14
53	Nucleation of Elusive Crystal Polymorphs at the Solution–Substrate Contact Line. Crystal Growth and Design, 2013, 13, 1180-1186.	3.0	30
54	PAT-Enabled Determination of Design Space for Seeded Cooling Crystallization. Organic Process Research and Development, 2013, 17, 549-556.	2.7	10

#	Article	IF	CITATIONS
55	Co-Crystals and Co-Crystal Hydrates of the Antibiotic Nitrofurantoin: Structural Studies and Physicochemical Properties. Crystal Growth and Design, 2012, 12, 5925-5938.	3.0	72
56	Glycine Open Dimers in Solution: New Insights into \hat{l}_{\pm} -Glycine Nucleation and Growth. Crystal Growth and Design, 2012, 12, 4771-4778.	3.0	46
57	Polymorphism and phase transformations of a cocrystal of nicotinamide and pimelic acid. CrystEngComm, 2012, 14, 8193.	2.6	30
58	Pharmaceutical cocrystals of ethenzamide: structural, solubility and dissolution studies. CrystEngComm, 2012, 14, 8515.	2.6	71
59	The solvates of sulfamerazine: structural, thermochemical, and desolvation studies. CrystEngComm, 2012, 14, 691-699.	2.6	44
60	Cocrystal Hydrate of an Antifungal Drug, Griseofulvin, with Promising Physicochemical Properties. Crystal Growth and Design, 2012, 12, 5858-5863.	3.0	61
61	Strong Additive–Surface Interaction Leads to the Unusual Revival of Growth at Solvent-Poisoned Faces of <scp>dl</scp> -Alanine Crystal. Crystal Growth and Design, 2012, 12, 5555-5560.	3.0	14
62	Operating Strategy to Produce Consistent CSD in Combined Antisolvent-Cooling Crystallization Using FBRM. Industrial & Engineering Chemistry Research, 2012, 51, 13773-13783.	3.7	22
63	Direct Comparison of \hat{l}_{\pm} - and \hat{l}_{\pm} -Glycine Growth Rates in Acidic and Basic Solutions: New Insights into Glycine Polymorphism. Crystal Growth and Design, 2012, 12, 2213-2220.	3.0	45
64	Co-crystals of caffeine and piracetam with 4-hydroxybenzoic acid: Unravelling the hidden hydrates of 1 : 1 co-crystals. CrystEngComm, 2012, 14, 2381.	2.6	36
65	Comparison of dielectric constant meter with turbidity meter and focused beam reflectance measurement for metastable zone width determination. Chemical Engineering Research and Design, 2012, 90, 259-265.	5 . 6	7
66	Quality by Design (QbD)-Based Crystallization Process Development for the Polymorphic Drug Tolbutamide. Crystal Growth and Design, 2011, 11, 3027-3038.	3.0	40
67	Precise Habit Modification of Polar <scp>dl</scp> -Alanine Crystal by Control of Supersaturation. Crystal Growth and Design, 2011, 11, 3941-3946.	3.0	18
68	Nitrofurantoin methanol monosolvate. Acta Crystallographica Section E: Structure Reports Online, 2011, 67, o550-o551.	0.2	4
69	Supersaturation Control in Cooling Polymorphic Co-Crystallization of Caffeine and Glutaric Acid. Crystal Growth and Design, 2011, 11, 4525-4532.	3.0	35
70	Conformational Polymorphs of a Muscle Relaxant, Metaxalone. Crystal Growth and Design, 2011, 11, 4101-4109.	3.0	24
71	The Effect and Counter-Effect of Impurities on Crystallization of an Agrochemical Active Ingredient: Stereochemical Rationalization and Nanoscale Crystal Growth Visualization. Crystal Growth and Design, 2011, 11, 492-500.	3.0	18
72	Solvates and polymorphic phase transformations of 2-chloro-4-nitrobenzoic acid. CrystEngComm, 2011, 13, 1037-1045.	2.6	38

#	Article	IF	CITATIONS
73	Molecular Simulation Study of the Effect of Various Additives on Salbutamol Sulfate Crystal Habit. Molecular Pharmaceutics, 2011, 8, 1910-1918.	4.6	72
74	Solvates and a monohydrate of N4-acetylsulfamerazine: Structural, thermochemical, and computational analysis. Journal of Molecular Structure, 2011, 1005, 134-140.	3.6	7
75	Calibration of dielectric constant measurements to improve the detection of cloud and clear points in solution crystallization. Chemical Engineering Research and Design, 2011, 89, 2613-2619.	5.6	8
76	Characterization, physicochemical and photo-stability of a co-crystal involving an antibioticdrug, nitrofurantoin, and 4-hydroxybenzoic acid. CrystEngComm, 2011, 13, 759-762.	2.6	92
77	Structural, Spectroscopic and Thermal Analysis of Cocrystals of Carbamazepine and Piracetam with Hydroquinone. Journal of Chemical Crystallography, 2011, 41, 1604-1611.	1.1	11
78	Quantification of polymorphic impurity in an enantiotropic polymorph system using differential scanning calorimetry, X-ray powder diffraction and Raman spectroscopy. International Journal of Pharmaceutics, 2011, 415, 110-118.	5.2	53
79	Effects of the rate of supersaturation generation on polymorphic crystallization of m-hydroxybenzoic acid and o-aminobenzoic acid. Journal of Crystal Growth, 2011, 314, 220-226.	1.5	16
80	Pyrimidin-2-amine–1-phenylcyclopentane-1-carboxylic acid (1/1). Acta Crystallographica Section E: Structure Reports Online, 2011, 67, o552-o553.	0.2	2
81	N,N-Dimethylpyridin-4-aminium 1-phenylcyclopentane-1-carboxylate monohydrate. Acta Crystallographica Section E: Structure Reports Online, 2011, 67, o1227-o1227.	0.2	0
82	Conformational Polymorphism of Tolbutamide: A Structural, Spectroscopic, and Thermodynamic Characterization of Burger's Forms l–IV. Journal of Pharmaceutical Sciences, 2010, 99, 2975-2990.	3.3	62
83	2-Aminopyridinium 1-phenylcyclopropane-1-carboxylate. Acta Crystallographica Section E: Structure Reports Online, 2010, 66, o3339-o3340.	0.2	2
84	Ethenzamide–gentisic acid–acetic acid (2/1/1). Acta Crystallographica Section E: Structure Reports Online, 2010, 66, o1045-o1046.	0.2	10
85	Understanding Growth Morphology Changes of \hat{I}^3 -Glycine and $\langle scp \rangle dl \langle scp \rangle$ -Alanine Polar Crystals in Pure Aqueous Solutions. Crystal Growth and Design, 2010, 10, 4883-4889.	3.0	40
86	Implementation of Focused Beam Reflectance Measurement (FBRM) in Antisolvent Crystallization to Achieve Consistent Product Quality. Crystal Growth and Design, 2010, 10, 3668-3674.	3.0	27
87	In Situ Determination of Metastable Zone Width Using Dielectric Constant Measurement. Organic Process Research and Development, 2010, 14, 1469-1472.	2.7	19
88	Investigating the Intermolecular Interactions in Concentration-Dependent Solution Cocrystallization of Caffeine and <i>p</i> Hydroxybenzoic Acid. Crystal Growth and Design, 2010, 10, 3763-3769.	3.0	22
89	Direct Precipitation of Micron-Size Salbutamol Sulfate: New Insights into the Action of Surfactants and Polymeric Additives. Crystal Growth and Design, 2010, 10, 3363-3371.	3.0	58
90	Conformational and enantiotropic polymorphism of a 1 : 1 cocrystal involving ethenzamide and ethylmalonic acid. CrystEngComm, 2010, 12, 3691.	2.6	58

#	Article	IF	CITATIONS
91	Polymorphs and Solvates of a Cocrystal Involving an Analgesic Drug, Ethenzamide, and 3,5-Dinitrobenzoic Acid. Crystal Growth and Design, 2010, 10, 2229-2238.	3.0	109
92	Operating Regions in Cooling Cocrystallization of Caffeine and Glutaric Acid in Acetonitrile. Crystal Growth and Design, 2010, 10, 2382-2387.	3.0	87
93	Acceleration of crystal growth rates: an unexpected effect of tailor-made additives. Chemical Communications, 2010, 46, 5924.	4.1	88
94	Theophylline–gentisic acid (1/1). Acta Crystallographica Section E: Structure Reports Online, 2009, 65, o2126-o2127.	0.2	9
95	Trimorphs of a pharmaceutical cocrystal involving two active pharmaceutical ingredients: potential relevance to combination drugs. CrystEngComm, 2009, 11, 1823-1827.	2.6	134
96	Residence Time Distribution of Liquid and Solid Phases in a Novel Staged Crystallizer. Industrial & Engineering Chemistry Research, 2009, 48, 10047-10054.	3.7	1
97	Dimorphs of a 1 : 1 cocrystal of ethenzamide and saccharin: solid-state grinding methods result in metastable polymorph. CrystEngComm, 2009, 11, 889.	2.6	73
98	Predicting Multicomponent Crystal Formation: The Interplay between Homomeric and Heteromeric Interactions. Crystal Growth and Design, 2009, 9, 4529-4532.	3.0	30
99	Synthesis of carboxyl-modified rod-like SBA-15 by rapid co-condensation. Journal of Colloid and Interface Science, 2008, 321, 365-372.	9.4	46
100	Effect of solution speciation of impurities on \hat{l} ±-glycine crystal habit: A molecular modeling study. Journal of Crystal Growth, 2008, 310, 3034-3041.	1.5	31
101	Effect of Water Activity on the Transformation between Hydrate and Anhydrate of Carbamazepine. Organic Process Research and Development, 2008, 12, 264-270.	2.7	64
102	Screening for Cocrystallization Tendency: The Role of Intermolecular Interactions. Journal of Physical Chemistry B, 2008, 112, 9890-9895.	2.6	31
103	Influence of Solution Speciation of Impurities on Polymorphic Nucleation in Glycine. Crystal Growth and Design, 2008, 8, 179-185.	3.0	66
104	Interpretation of Focused Beam Reflectance Measurement (FBRM) Data via Simulated Crystallization. Organic Process Research and Development, 2008, 12, 646-654.	2.7	49
105	Impurity Effects on the Growth of Molecular Crystals: Experiments and Modeling. Advanced Powder Technology, 2008, 19, 459-473.	4.1	13
106	Submicron Particles of SBA-15 Modified with MgO as Carriers for Controlled Drug Delivery. Chemical and Pharmaceutical Bulletin, 2007, 55, 985-991.	1.3	63
107	Stable polymorphs: difficult to make and difficult to predict. CrystEngComm, 2007, 9, 128.	2.6	62
108	Steam-Assisted Solid Wet-Gel Synthesis of High-Quality Nanorods of Boehmite and Alumina. Journal of Physical Chemistry C, 2007, 111, 700-707.	3.1	96

#	Article	IF	CITATIONS
109	Automated In-line Technique Using FBRM to Achieve Consistent Product Quality in Cooling Crystallization. Crystal Growth and Design, 2007, 7, 1416-1422.	3.0	47
110	Comparison between Open-Loop Temperature Control and Closed-Loop Supersaturation Control for Cooling Crystallization of Glycine. Industrial & Engineering Chemistry Research, 2007, 46, 830-838.	3.7	31
111	Molecular Speciation Controlling Stereoselectivity of Additives: Impact on the Habit Modification in α-Glycine Crystals. Crystal Growth and Design, 2007, 7, 254-261.	3.0	42
112	Quantification of particle morphology by boundary Fourier transform and generic Fourier transform. Chemical Engineering Science, 2007, 62, 3777-3786.	3.8	10
113	Multivariate data analysis as a tool to investigate the reaction kinetics of intramolecular cyclization of enalapril maleate studied by isothermal and non-isothermal FT-IR microscopy. European Journal of Pharmaceutical Sciences, 2007, 32, 349-356.	4.0	8
114	Simulation of Mixing Effects in Antisolvent Crystallization Using a Coupled CFD-PDF-PBE Approach. Crystal Growth and Design, 2006, 6, 1291-1303.	3.0	106
115	Seeding and Constant-Supersaturation Control by ATR-FTIR in Anti-Solvent Crystallization. Organic Process Research and Development, 2006, 10, 717-722.	2.7	39
116	Application of Attenuated Total Reflectanceâ^'Fourier Transform Infrared (ATRâ^'FTIR) Technique in the Monitoring and Control of Anti-solvent Crystallization. Industrial & Engineering Chemistry Research, 2006, 45, 438-444.	3.7	55
117	Synthesis of SBA-15 mesoporous silica via dry-gel conversion route. Microporous and Mesoporous Materials, 2006, 92, 300-308.	4.4	40
118	Synthesis of submicron gibbsite platelets by organic-free hydrothermal crystallization process. Journal of Crystal Growth, 2006, 292, 136-142.	1.5	36
119	Spherulitic growth kinetics of protein crystals. Applied Physics Letters, 2002, 81, 1975-1977.	3.3	21
120	SPHERULITIC GROWTH IN PROTEIN SOLUTIONS. International Journal of Modern Physics B, 2002, 16, 354-358.	2.0	8
121	Paracetamol Crystallization Using Laser Backscattering and ATR-FTIR Spectroscopy:  Metastability, Agglomeration, and Control. Crystal Growth and Design, 2002, 2, 363-370.	3.0	238